During the corresponding time, Anaptysbio Inc saw a revenue deteriorated by -7.98 % year on year, sequentially revenue fell by -76.39 %. While revenue at the Anaptysbio Inc 's corporate clients
Anaptysbio Inc's Comment on Sales, Marketing and Customers
The company serves customers through collaboration and license agreements that include performance obligations such as license arrangements, research and development services, and participation in steering committee meetings. Licenses grant exclusive or nonexclusive rights to products developed using the company's technologies, primarily antibodies in the discovery phase. Research and development services are conducted on behalf of or with collaborators, mainly involving internally generated antibodies that require a license for third-party use. Participation in steering committees guides discovery programs. Revenue is recognized as performance obligations are fulfilled, typically over the duration of the research and development services. No new agreements with performance obligations were entered into during the year ended December 31, 2025.
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company dedicated to developing innovative immunology therapeutics, has recently disclosed promising clinical trial outcomes for two of its lead investigational drugs. The announcement was made during the American College of Rheumatology (ACR) Convergence 2025 in Chicago and includes significant progress in the development of treatments for rheumatoid arthritis (RA) and generalized pustular psoriasis (GPP). Phase 2b Rosnilimab Trial for Rheumatoid Arthritis A focal point of AnaptysBio s recent announcement is the new data from a global 424-patient Phase 2b trial of rosnilimab, presented at the ACR Convergence 2025. Rosnilimab, a selective and po...
Anaptysbio Inc’s Comment on Sales, Marketing and Customers
The company serves customers through collaboration and license agreements that include performance obligations such as license arrangements, research and development services, and participation in steering committee meetings. Licenses grant exclusive or nonexclusive rights to products developed using the company's technologies, primarily antibodies in the discovery phase. Research and development services are conducted on behalf of or with collaborators, mainly involving internally generated antibodies that require a license for third-party use. Participation in steering committees guides discovery programs. Revenue is recognized as performance obligations are fulfilled, typically over the duration of the research and development services. No new agreements with performance obligations were entered into during the year ended December 31, 2025.
Sources:
Anaptysbio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Anaptysbio Inc’s corporate clients.
For your research, we’ve provided 9 tables on Anaptysbio Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
100 %